ABSTRACT
To explore the therapeutic effect and safety of target-dose metoprolol in treating chronic heart failure [CHF] patients complicated with diabetes mellitus [DM]. One hundred and fifty-four elderly patients were randomly divided into an observation group and a control group [n=77], which were treated with target-dose metoprolol and conventional therapy, and routinely treated respectively. The New York Heart Association [NYHA] classification, left ventricular end-systolic diameter [LVESD], left ventricular end-diastolic diameter [LVEDD], left ventricular ejection fraction [LVEF], 6-min walking distance and medication safety of the two groups were compared. Compared with the results before treatment, the NYHA classification, LVESD, LVEDD, LVEF and 6-minutes walking distance of both groups were significantly improved [P < 0.05], with significantly better results in the observation group than those in the control group after treatment [P < 0.05]. In the 6 months of follow-up, the incidence of cardiac events in the observation group [3.90%] was significantly lower than that of the control group [14.29%] [P < 0.05]. The levels of average fasting blood sugar and glycosylated hemoglobin in the groups showed no significant differences [P > 0.05]. Treating CHF patients complicated with DM with target-dose metoprolol can obviously boost the cardiac function and exercise tolerance, leading to satisfactory clinical therapeutic effect, high security and moderate tolerance